Table 5

Lipid parametersa in the all-exposed population (n = 4,009)

Parameter (mg/dl)

Baseline

Week 6

Week 52b

Week 104


Mean total cholesterol

196.2

(n = 3,714)

227.6

(n = 3,279)

222.9

(n = 1,312)

224.1

(n = 828)

Mean LDL cholesterol

114.2

(n = 3,633)

135.5

(n = 3,149)

133.5

(n = 1,274)

134.3

(n = 805)

Mean HDL cholesterol

56.9

(n = 3,656)

60.8

(n = 3,249)

60.0

(n = 1,301)

60.0

(n = 826)

Mean triglycerides

127.6

(n = 3,715)

160.4

(n = 3,280)

148.8

(n = 1,312)

148.8

(n = 828)

Patients starting lipid-lowering medication

at any time up to week 104 during the trial (n = 456)

Mean total cholesterol

223.3

(n = 415)

267.4

(n = 375)

247.7

(n = 154)

236.1

(n = 109)

Mean LDL cholesterol

135.1

(n = 402)

167.6

(n = 338)

152.9

(n = 142)

138.9

(n = 97)


HDL, high-density lipoprotein; LDL, low-density lipoprotein. aFasted samples only. bPatient numbers declined after week 6 because patients' 12-week fasted lipid-analysis schedules might not have coincided with week 52, depending on when they started tocilizumab treatment (that is, some patients had their fasted lipid analysis at week 48 or week 56).

Schiff et al. Arthritis Research & Therapy 2011 13:R141   doi:10.1186/ar3455

Open Data